In order for the Aceragen website to work properly, we place functional cookies. Aceragen also places analytical cookies to determine which parts of the website are most interesting for you as visitors. In addition, Aceragen uses cookies to analyze our ads and traffic and to provide social media features.
Our Pipeline
| Pre-clinical | Phase 1 | Phase 2 | Phase 3 | ||
|---|---|---|---|---|---|
|
ACG-801
(acid ceramidase)
|
Farber disease
|
||||
|
ACG-701
(sodium fusidate)
|
Melioidosis
|
||||
|
Cystic fibrosis
(PEx treatment)
|
|||||
Expanded Access
Aceragen intends to execute clinical programs for its lead investigational products, ACG-701 and ACG-801. Please watch this site for updates on our progress toward this goal or you can contact us directly at info@aceragen.com. Under section 561(b) of the FD&C Act, Aceragen’s medical staff and advisors will evaluate Expanded Access requests following review of Phase III clinical data. All such requests should be initiated via the designated contact form.